Catalyst

Slingshot members are tracking this event:

Regeneron (REGN) and Sanofi (SNY) to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016

Source Link:
http://www.prnewswire.com/news-releases/regeneron-and-sanofi-to-present-data-from-phase-3-praluent-alirocumab-injection-clinical-trials-at-aha-scientific-sessions-2016-300361313.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
REGN Community voting in process
SNY Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 12, 2016
Occurred Source:
http://files.shareholder.com/downloads/REGN/2696791652x0x917135/8527A77A-6373-417C-B774-873D25231F0A/REGN_News_2016_11_11_General_Releases.pdf
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Praluent, Alirocumab, Aha Scientific Sessions 2016, Phase 3, Odyssey
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.